Fig. 2: Sensitivity of the SARS-CoV-2 variants D614G, Alpha, Beta and Delta to sera from convalescent individuals and vaccinated individuals.
From: Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization
Neutralization titres of the sera against the indicated viral isolates are expressed as ED50 values. a, Neutralizing activity of sera from the Strasbourg cohort of convalescent individuals (n = 26; left) and convalescent individuals who had been vaccinated (n = 21; right). Samples were collected at month 12 (M12) after the onset of symptoms. b, Neutralizing activity of sera from recipients of the Pfizer vaccine, sampled at week 3 (W3) after vaccination (n = 16; left) and week 8 (W8) after vaccination (week 5 after the second dose) (n = 16; right). c, Neutralizing activity of sera from recipients of the AstraZeneca vaccine, sampled at week 10 (W10) after vaccination (n = 23; left) and week 16 (W16) after vaccination (week 4 after the second dose) (n = 20; right). The dotted line indicates the limit of detection (ED50 = 30). Data are mean from two independent experiments. A two-sided Friedman test with Dunn’s multiple comparison was performed between each of the viral strains. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. Strasbourg cohort, unvaccinated (M12): D614G versus Beta, P = 0.0052; D614G versus Delta, P = 0.0052; Alpha versus Beta, P < 0.0001; Alpha versus Delta, P < 0.0001. Strasbourg cohort, vaccinated (M12): D614G versus Beta, P < 0.0001; Alpha versus Beta, P < 0.0001; Alpha versus Delta, P < 0.0001. Pfizer (W3): D614G versus Beta, P = 0.0001; D614G versus Delta, P = 0.0013. Pfizer (W8): D614G versus Beta, P = 0.0002; Alpha versus Beta, P < 0.0001; Alpha versus Delta, P = 0.0098. AstraZeneca (W10): D614G versus Beta, P < 0.0001; D614G versus Delta, P < 0.0001; Alpha versus Beta, P = 0.0006; Alpha versus Delta, P = 0.0056. AstraZeneca (W16): D614G versus Beta, P < 0.0001; D614G versus Delta, P = 0.0005, Alpha versus Beta, P < 0.0001; Alpha versus Delta, P < 0.0001.
